NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

Tenax Therapeutics logo
$7.20 -0.10 (-1.37%)
Closing price 02/14/2025 03:58 PM Eastern
Extended Trading
$7.22 +0.02 (+0.29%)
As of 02/14/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tenax Therapeutics Stock (NASDAQ:TENX)

Key Stats

Today's Range
$7.11
$7.45
50-Day Range
$5.49
$7.76
52-Week Range
$2.77
$7.89
Volume
14,197 shs
Average Volume
38,973 shs
Market Capitalization
$24.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Buy

Company Overview

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Tenax Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

TENX MarketRank™: 

Tenax Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 717th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tenax Therapeutics has received no research coverage in the past 90 days.

  • Read more about Tenax Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.

  • Price to Book Value per Share Ratio

    Tenax Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Tenax Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.29% of the float of Tenax Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenax Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tenax Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Tenax Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tenax Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.29% of the float of Tenax Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tenax Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tenax Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving.
  • Search Interest

    2 people have searched for TENX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.70% of the stock of Tenax Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

  • Read more about Tenax Therapeutics' insider trading history.
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TENX Stock News Headlines

Leerink Partnrs Brokers Reduce Earnings Estimates for TENX
Forget morning trades: Here’s when real money moves
When 12pm Eastern rolls around… Something really special happens. It’s the first hour of the day that the overseas markets are closed… And it’s the FIRST time that we can see Wall Street trading freely on their own – without the noise from the international markets… That’s why we see so many opportunities during the Genesis Hour. And anyone who can spot stocks breaking out during the 12 pm Genesis Hour can then jump in ahead of what could be the next big move… Intrigued? You should be! Because it’s one of the most exciting, little-known revelations I’ve uncovered in my 40+ years trading the markets. If you’d like to join him for a deeper dive…
See More Headlines

TENX Stock Analysis - Frequently Asked Questions

Tenax Therapeutics' stock was trading at $6.19 on January 1st, 2025. Since then, TENX shares have increased by 16.3% and is now trading at $7.20.
View the best growth stocks for 2025 here
.

Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Tuesday, August, 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping analysts' consensus estimates of ($1.99) by $0.16.

Shares of Tenax Therapeutics reverse split on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional investors of Tenax Therapeutics include Janus Henderson Group PLC (4.89%), Vestal Point Capital LP (1.62%), ADAR1 Capital Management LLC (1.02%) and Millennium Management LLC (0.79%).
View institutional ownership trends
.

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/13/2024
Today
2/17/2025
Next Earnings (Estimated)
3/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TENX
Employees
9
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+122.2%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-7,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$27.15 per share

Miscellaneous

Free Float
3,283,000
Market Cap
$24.55 million
Optionable
Not Optionable
Beta
2.14

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:TENX) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners